{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:43:00Z","timestamp":1782351780480,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.autrev.2018.09.012","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T22:46:26Z","timestamp":1547160386000},"page":"255-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis"],"prefix":"10.1016","volume":"18","author":[{"given":"Johann","family":"Sellner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus Stefan","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.09.012_bb0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","article-title":"Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring","volume":"6","author":"Kappos","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0010","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.autrev.2018.04.005","article-title":"The role of stress in the mosaic of autoimmunity: an overlooked association","volume":"17","author":"Sharif","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.012_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2018.07.006","article-title":"Polymerase-1 pathway activation in acute multiple sclerosis relapse","author":"Achiron","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.012_bb0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","article-title":"Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review","volume":"16","author":"Merkel","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.012_bb0025","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/ijms18050940","article-title":"Natalizumab in multiple sclerosis: long-term management","volume":"18","author":"Clerico","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2018.09.012_bb0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.09.012_bb0035","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"SENTINEL investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.09.012_bb0040","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s00415-012-6414-9","article-title":"Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study","volume":"259","author":"Fern\u00e1ndez","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2012.08.027","article-title":"Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis","volume":"323","author":"Prosperini","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2018.09.012_bb0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","article-title":"Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis","volume":"18","author":"Belachew","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0055","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0060","series-title":"Physician information and management guidelines for multiple sclerosis patients on TYSABRI therapy. Version 17","author":"Biogen","year":"2017"},{"key":"10.1016\/j.autrev.2018.09.012_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.671","article-title":"Catastrophic outcome of patients with a rebound after natalizumab treatment discontinuation","volume":"7","author":"Gonz\u00e1lez-Suarez","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.autrev.2018.09.012_bb0070","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamaneurol.2014.1200","article-title":"Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)","volume":"71","author":"Clerico","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24051","article-title":"Progressive multifocal leukoencephalopathy after natalizumab discontinuation","volume":"75","author":"Fine","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2018.09.012_bb0085","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2018.09.012_bb0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2377-13-101","article-title":"Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial","volume":"13","author":"Gobbi","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0095","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00415-011-5996-y","article-title":"De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate","volume":"258","author":"Havla","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0100","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00415-011-6019-8","article-title":"Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study","volume":"258","author":"Magraner","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1468-1331.2012.03794.x","article-title":"Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab","volume":"20","author":"Rossi","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000453333","article-title":"Observational Study of Switching from Natalizumab to immunomodulatory drugs","volume":"77","author":"Villaverde-Gonz\u00e1lez","year":"2017","journal-title":"Eur Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0115","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/1352458512468498","article-title":"Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption","volume":"19","author":"Laroni","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2018.09.012_bb0120","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Italian iMed-Web database. Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis","volume":"138","author":"Iaffaldano","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2018.09.012_bb0125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.msard.2014.04.003","article-title":"Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients","volume":"3","author":"Sangalli","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2018.09.012_bb0130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/ene.12487","article-title":"No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation","volume":"22","author":"Capobianco","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/cns.12282","article-title":"Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroids","volume":"20","author":"Rossi","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2018.09.012_bb0140","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00415-016-8162-8","article-title":"Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors","volume":"263","author":"Zurawski","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0145","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/jnnp-2017-316236","article-title":"Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events","volume":"88","author":"Calabrese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2018.09.012_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","article-title":"Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY)","volume":"22","author":"Cohan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2018.09.012_bb0155","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","article-title":"Fingolimod after natalizumab and the risk of short-term relapse","volume":"82","author":"Jokubaitis","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2018.09.012_bb0160","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1590\/0004-282X20160090","article-title":"Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis","volume":"74","author":"Fragoso","year":"2016","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.autrev.2018.09.012_bb0165","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00415-012-6808-8","article-title":"Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis","volume":"260","author":"Havla","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0170","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458512464282","article-title":"Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2018.09.012_bb0175","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/ane.12082","article-title":"Switching from natalizumab to fingolimod: an observational study","volume":"128","author":"Sempere","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2018.09.012_bb0180","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1177\/1352458514533398","article-title":"Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod","volume":"20","author":"Hoepner","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2018.09.012_bb0185","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418791103","article-title":"Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod","volume":"11","author":"Diem","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2018.09.012_bb0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2018.09.012_bb0195","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","article-title":"Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study","volume":"71","author":"Cohen","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0200","article-title":"Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients","volume":"1","author":"Leurs","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2018.09.012_bb0205","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/1352458513490551","article-title":"Reduction of the washout time between natalizumab and fingolimod","volume":"19","author":"de Seze","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2018.09.012_bb0210","first-page":"1","article-title":"Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis","volume":"21","author":"Fragoso","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0215","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3109\/00207454.2015.1127919","article-title":"Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod","volume":"126","author":"Evangelopoulos","year":"2016","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.autrev.2018.09.012_bb0220","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0225","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10072-017-3228-7","article-title":"Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?","volume":"39","author":"Mancinelli","year":"2018","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2018.09.012_bb0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40120-016-0058-0","article-title":"High-risk PML patients switching from natalizumab to alemtuzumab: an observational study","volume":"6","author":"Malucchi","year":"2017","journal-title":"Neurol Ther"},{"issue":"15 Suppl","key":"10.1016\/j.autrev.2018.09.012_bb0235","article-title":"Efficacy and safety of alemtuzumab in real world Italian patients switching from natalizumab (P6.357)","volume":"90","author":"Bertolotto","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2018.09.012_bb0240","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00415-017-8622-9","article-title":"Disease reactivation after switching from natalizumab to daclizumab","volume":"264","author":"Uphaus","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2018.09.012_bb0245","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.msard.2018.03.021","article-title":"Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab","volume":"22","author":"H\u00fcmmert","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.autrev.2018.09.012_bb0250","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2018.09.012_bb0255","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2018.09.012_bb0260","series-title":"Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS); San Diego, CA; USA: LB250","article-title":"Natalizumab extended interval dosing is associated with a reduction in progressive multifocal leukoencephalopathy risk in the TOUCH\u00ae Registry","author":"Zhovtis Ryerson","year":"2018"},{"key":"10.1016\/j.autrev.2018.09.012_bb0265","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.autrev.2018.09.012_bb0270","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.autrev.2018.09.012_bb0275","author":"ClinicalTrials.gov"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:13:07Z","timestamp":1761599587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219300059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1568997219300059"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.09.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}